Despite their poor sensitivity in detecting advanced fibrosis in patients with type 2 diabetes [63], these scores (FIB-4 is among best studied) [64, 65] have reasonable specificity and can be convenient for healthcare providers to assess patients with suspected NAFLD based on US or elevated levels of ALT [58, 66] (Fig. 3). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.